Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to improving and extending the lives of patients with cancer by enabling better targeting of therapies, early detection of treatment resistance and routine monitoring of treatment response.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/03/24 | $24,000,000 |
Agilent Technologies BlueYard Capital Longwall Ventures Octopus Ventures | undisclosed |
